In AML, single-cell multi-omics revealed TP53 mutations in T and NK cells, with T cells showing elevated proliferative markers but reduced cytotoxicity and increased expression of inhibitory receptors such as PD-1, TIGIT, and TIM-3. This evidence concerns the gene TP53 and acute myeloid leukemia.